ERC Society for Endocrinology Archive
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Accepted Preprint first posted online on 4 March 2009

Endocrine-Related Cancer 2009;16:455.

DOI: 10.1677/ERC-09-0002
Copyright © 2009 by the Society for Endocrinology.
This Article
Right arrow Accepted manuscript (PDF)
Right arrow All Versions of this Article:
ERC-09-0002v1
16/2/455    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cheng, S.
Right arrow Articles by Asa, S. L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cheng, S.
Right arrow Articles by Asa, S. L

RESEARCH

Expression of the melanoma associated (MAGE) antigen is associated with progression of human thyroid cancer

Sonia Cheng, Wei Liu, Moisés Mercado, Shereen Ezzat and Sylvia L Asa

S Cheng, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada
W Liu, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada
M Mercado,
S Ezzat, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada
S Asa, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada

Correspondence: Sylvia L Asa, Email: sylvia.asa{at}uhn.on.ca

Abstract

Thyroid cancer exhibits a spectrum from relatively indolent tumors to tumors that are invasive, metastatic or progress to poorly differentiated carcinoma. Microarray expression analysis of thyroid cancer cell lines has implicated a member of the Melanoma Associated (MAGE) family of cancer-testis antigens in thyroid cancer development and progression. We performed this study to validate the role of MAGE in human thyroid cancers. A tissue microarray (TMA) of samples from 375 patients with thyroid cancer was analyzed with immunohistochemistry (IHC) to localize MAGE. Western blotting of fractionated proteins from MAGE-transfected cells was used to confirm intracellular localization of proteins. Automated analysis of TMA samples was evaluated and subjected to statistical analysis. MAGE immunoreactivity was identified in nuclear and cytoplasmic compartments of normal and malignant tissues. Specificity of staining was proved by fractionation studies that confirmed MAGE expression in nucleus and cytoplasm. Normal thyroid tissue exhibited weak cytoplasmic and strong nuclear MAGE reactivity. Tumors exhibited an increase in cytoplasmic MAGE scores that correlated with clinical behavior: larger tumors had higher MAGE scores, and there was a positive and significant correlation between MAGE cytoplasmic score and the number of histologically-proven lymph node metastases. There was a statistically significant negative correlation between cytoplasmic MAGE and the percentage of p53 positive nuclei. Our data confirm gene profiling evidence that members of the MAGE family play a role in thyroid cancer progression. The use of TMA analyses identifies IHC techniques that are translatable to the clinical setting for prognostic assessment of patients with thyroid cancer.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2009 by the Society for Endocrinology.